NexPoint Life Sciences III is a 137,811 SF, 2021-vintage single-tenant life-sciences facility in Woodbury, MN (Minneapolis-St. Paul MSA), net-leased to pharmaceutical CDMO Kindeva Drug Delivery through September 2036 with three extension options. The asset is held subject to a master lease to a thinly capitalized, unaffiliated master tenant funded by a $1.9M sponsor-financed demand note, and was capitalized at $61.96M ($30.66M equity + $31.3M assumed Wings Financial loan). Distributions are projected to begin at 4.18% and range 4.01%-4.10% thereafter, with the nine-year forecast aligned to the November 2032 loan maturity.
73 acres at 11200 Hudson Road, Woodbury, Minnesota (Minneapolis-St. S. , a global pharmaceutical CDMO specializing in drug-device combination products (pulmonary/nasal, injectable, transdermal delivery) and backed by private-equity sponsor Altaris Capital Partners. The Trust holds the asset subject to a Master Lease to 11200 Hudson Leaseco, LLC, an unaffiliated, thinly capitalized newly-formed Master Tenant funded by a $1,900,000 Sponsor-financed Demand Note that subleases to Kindeva under a 15-year Tenant Lease commenced September 17, 2021 and expiring September 30, 2036 with three five-year extension options, structured as a net lease under which the Tenant bears maintenance and services and the Master Tenant passes through taxes, insurance, and utilities.
The Property was acquired indirectly by a Sponsor affiliate for a $57,750,000 MIPA price against a $59,000,000 BBG as-is appraisal, capitalized at $61,961,253 comprising $30,661,253 of Class 1 equity and an assumed $31,300,000 Wings Financial Credit Union loan. The income thesis is single-tenant, in-place net-lease cash flow; the nine-year financial forecast aligns with the November 1, 2032 loan maturity and the Sponsor's business plan contemplates disposition within approximately five to nine years. 10% thereafter, partially shielded by depreciation. The offering is a best-efforts Regulation D placement whose termination date has been extended serially from January 31, 2025 to January 31, 2026 and then to July 31, 2026.
| Lender | Wings Financial Credit Union |
| Interest Rate | 4.50% (Fixed) |
| Loan Term | 10 years |
| Interest-Only Period | 3 years |
| Amortization | 25 years |
| Total Debt | $31.3M ($31,300,000) |
| In-Place LTV | 50.52% |
| Year 1 DSCR | 2.56x |
The asset is 100% net-leased to Kindeva Drug Delivery L.P., a global contract development and manufacturing organization focused on drug-device combination products that operates nine facilities across the U.S. and U.K. and is backed by Altaris Capital Partners, under a 15-year lease commenced September 2021 and running to September 30, 2036 with three five-year extension options; the long-dated term extends roughly three years beyond both the November 2032 loan maturity and the planned disposition window, providing a contracted income stream with no rollover exposure during the hold.
The 2021-vintage, purpose-built 137,811 RSF facility on 11.73 acres constitutes mission-critical, build-to-suit pharmaceutical manufacturing and R&D real estate in the Minneapolis–St. Paul MSA, one of the highest-ranked U.S. life science clusters; specialized fill-finish, container-closure, and drug-device assembly infrastructure elevates tenant switching costs and supports retention economics that generic office or industrial product cannot replicate.
Going-in leverage is moderate at a 50.52% loan-to-capitalization, $31,300,000 against $61,961,253 of total capitalization, and the in-place yield produces positive leverage against the 4.50% fixed coupon during the interest-only window, generating Year 1 net operating income that covers debt service at roughly 2.56x before amortization commences.
The assumed Wings Financial Credit Union facility carries a 4.50% fixed coupon with 36 months of interest-only payments, front-loading distributable cash flow and supporting the 4.18% Year 1 distribution before scheduled amortization beginning December 2025 on a 300-month schedule and the November 2029 rate reset compress coverage in the back half of the hold.
Distributions are projected to be partially tax-deferred through depreciation and amortization, and the structure embeds an Exchange Right under which the Sponsor's Exchange Entity may, after a one-year hold, call Holders' Interests for operating-partnership units in a transaction intended to qualify under Code Section 721 or 351, offering a potential UPREIT continuation path most single-asset DSTs lack, though the election rests with the Sponsor rather than the investor.
The offering presents a stabilized, single-tenant net-leased life sciences asset of recent 2021 construction in a premier life science MSA, leased to a global pharmaceutical CDMO under a long-dated 15-year term that extends beyond both loan maturity and the disposition window, eliminating in-hold rollover exposure. Leverage is moderate at a 50.52% loan-to-capitalization with a 4.50% fixed coupon through 2029 and interest-only payments that front-load coverage near 2.56x in Year 1, while the in-place yield produces positive leverage during the fixed-rate period. The net-lease structure minimizes landlord operating exposure, the specialized build-to-suit improvements raise tenant switching costs, distributions are projected to be partially tax-sheltered by depreciation, the capitalization is broadly corroborated by a third-party BBG as-is appraisal, and the structure preserves an optional Section 721/351 exchange continuation path.
The Tenant's contractual rent schedule embeds a pronounced step-down, with forecast net operating income declining approximately 11.67% in Year 4 as Master Lease Base Rent falls from $3,541,236 to $3,127,921 around 2027, pressuring distributable cash flow at the same time coverage is already eroding from the onset of amortization. The Master Tenant is a newly-formed, unaffiliated single-purpose entity with no substantial assets beyond its leasehold, capitalized only by a $1,900,000 Demand Note that was itself financed by the Sponsor, concentrating master-lease performance risk in a thinly capitalized counterparty whose support traces back to the Sponsor. The fixed 4.50% coupon expires in November 2029 and resets to a projected 6.25% at 2.00% over the three-year U.S. Treasury, driving scheduled debt service from roughly $1.41 million to as high as $2.48 million and compressing debt-service coverage toward approximately 1.38x by Year 7 before any adverse rate move. The underlying Tenant, Kindeva, is privately held with no public credit rating, leaving credit assessment dependent on a private-equity-owned CDMO in a cyclical pharmaceutical-services sector. Total capitalization of $61,961,253 exceeds both the $59,000,000 as-is appraisal and the $57,750,000 affiliate-acquisition price, embedding roughly $2.87 million of offering load that disposition pricing must overcome, and the exit is underwritten at a 4.50% terminal value against the entry basis, an approximately 130-basis-point compression assumption.
The analysis below is Baker 1031's educational opinion — not investment, tax, or legal advice, a recommendation, or a guarantee, and it does not replace the offering's Private Placement Memorandum (PPM), which governs in all respects. Read the PPM and consult your own CPA and attorney before investing.
The risk-adjusted profile is that of a single-tenant, net-leased life sciences credit-lease underwritten primarily for in-place income, with the principal variables residing in lease-schedule mechanics, counterparty depth, and refinancing rather than occupancy or the capital stack, which is moderately levered and fixed through 2029. The Minneapolis-St. Paul life science positioning and the mission-critical, build-to-suit nature of the improvements are genuine supports for tenant retention and residual value, and the lease term comfortably exceeds the hold, removing rollover risk from the base case. Against this, the underwriting embeds three coincident pressures - a Year 4 contractual rent decline, the commencement of amortization, and a 2029 reset to a projected 6.25% - that together compress coverage from roughly 2.56x to below 1.5x over the forecast even before the exit, leaving the 4.01%-4.10% distribution band with limited cushion if any assumption underperforms. The thin, Sponsor-financed Master Tenant capitalization and an entry basis above appraised value are the chief structural frictions, while the 4.50% terminal-value exit assumption against the entry basis is the most aggressive single assumption. Serial extension of the offering termination date through July 2026 indicates a measured placement pace for a best-efforts, no-minimum Regulation D offering.
The analysis below is Baker 1031's educational opinion — not investment, tax, or legal advice, a recommendation, or a guarantee, and it does not replace the offering's Private Placement Memorandum (PPM), which governs in all respects. Read the PPM and consult your own CPA and attorney before investing.
| Metric | This Offering | Market Avg. | Assessment |
|---|---|---|---|
| Avg. Income | 4.07% | 4.07% | Meets Average |
| Peak Income | 4.18% | 4.18% | Meets Average |
NexPoint
NexPoint is a Dallas alternative manager—an affiliate of the former Highland Capital complex—overseeing roughly $15 billion across listed and non-listed REITs, DSTs, 1031 exchanges, interval funds and a BDC. Its breadth across real estate and credit, paired with significant own-capital co-investment, gives it institutional heft in the exchange channel, and its concentrated Dallas/Uptown asset base reflects conviction in its home market. For exchangers, the platform offers a diversified menu backed by a sizable alternatives manager.
Learn More About NexPoint →Documents for this offering. Available to signed-in investors.
Securities offered through Aurora Securities, Inc. (CRD #46147 / SEC #8-51322), member FINRA / SIPC; Baker 1031 Investments, LLC is independent of Aurora Securities, Inc. and is not a registered broker-dealer or investment adviser. This is not an offer to sell or a solicitation of an offer to buy any security; any offer is made solely by the confidential private placement memorandum (PPM), which qualifies all information herein in its entirety. Delaware Statutory Trust interests are speculative, illiquid securities offered under Rule 506(c) of Regulation D and sold only to investors whose accredited-investor status has been verified; offering documents and subscription materials are provided only after that verification. They involve substantial risk, including possible loss of the entire investment.
Distributions, yields, the cap-rate equivalent, DSCR, occupancy, and benchmark figures are sponsor estimates or projections, are not guaranteed, and may differ materially from actual results. Any tax-adjusted yield assumes a 40% effective rate for non-1031 cash investors and is not tax advice. No tax, legal, or investment advice is provided — consult your own CPA and attorney. Past performance does not guarantee future results.